These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24365090)

  • 1. Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.
    Kastner R; Zopf A; Preuner S; Pröll J; Niklas N; Foskett P; Valent P; Lion T; Gabriel C
    Eur J Cancer; 2014 Mar; 50(4):793-800. PubMed ID: 24365090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
    Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
    Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
    Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
    Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
    Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
    Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
    Machova Polakova K; Kulvait V; Benesova A; Linhartova J; Klamova H; Jaruskova M; de Benedittis C; Haferlach T; Baccarani M; Martinelli G; Stopka T; Ernst T; Hochhaus A; Kohlmann A; Soverini S
    J Cancer Res Clin Oncol; 2015 May; 141(5):887-99. PubMed ID: 25367136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.
    Soverini S; Abruzzese E; Bocchia M; Bonifacio M; Galimberti S; Gozzini A; Iurlo A; Luciano L; Pregno P; Rosti G; Saglio G; Stagno F; Tiribelli M; Vigneri P; Barosi G; Breccia M
    J Hematol Oncol; 2019 Dec; 12(1):131. PubMed ID: 31801582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.
    Preuner S; Barna A; Frommlet F; Czurda S; Konstantin B; Alikian M; Machova Polakova K; Sacha T; Richter J; Lion T; Gabriel C
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27136541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing.
    Szankasi P; Schumacher JA; Kelley TW
    Ann Hematol; 2016 Jan; 95(2):201-10. PubMed ID: 26555285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.
    Soverini S; Albano F; Bassan R; Fabbiano F; Ferrara F; Foà R; Olivieri A; Rambaldi A; Rossi G; Sica S; Specchia G; Venditti A; Barosi G; Pane F
    Cancer Med; 2020 May; 9(9):2960-2970. PubMed ID: 32154668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia.
    Preuner S; Mitterbauer G; Mannhalter C; Herndlhofer S; Sperr WR; Valent P; Lion T
    Eur J Cancer; 2012 Jan; 48(2):233-6. PubMed ID: 21955823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia.
    Romzova M; Smitalova D; Tom N; Jurcek T; Culen M; Zackova D; Mayer J; Racil Z
    Br J Haematol; 2020 May; 189(3):469-474. PubMed ID: 32037516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Soverini S; Martelli M; Bavaro L; De Benedittis C; Papayannidis C; Sartor C; Sorà F; Albano F; Galimberti S; Abruzzese E; Annunziata M; Russo S; Stulle M; Imovilli A; Bonifacio M; Maino E; Stagno F; Maria Basilico C; Borlenghi E; Fozza C; Mignone F; Minari R; Stella S; Baccarani M; Cavo M; Martinelli G
    Br J Haematol; 2021 Apr; 193(2):271-279. PubMed ID: 33403687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
    Soverini S; Bavaro L; De Benedittis C; Martelli M; Iurlo A; Orofino N; Sica S; Sorà F; Lunghi F; Ciceri F; Galimberti S; Baratè C; Bonifacio M; Scaffidi L; Castagnetti F; Gugliotta G; Albano F; Russo Rossi AV; Stagno F; di Raimondo F; D'Adda M; di Bona E; Abruzzese E; Binotto G; Sancetta R; Salvucci M; Capodanno I; Girasoli M; Coluzzi S; Attolico I; Musolino C; Calistri E; Annunziata M; Bocchia M; Stella S; Serra A; Errichiello S; Saglio G; Pane F; Vigneri P; Mignone F; Laginestra MA; Pileri SA; Percesepe A; Tenti E; Rosti G; Baccarani M; Cavo M; Martinelli G
    Blood; 2020 Feb; 135(8):534-541. PubMed ID: 31877211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
    Khorashad JS; Kelley TW; Szankasi P; Mason CC; Soverini S; Adrian LT; Eide CA; Zabriskie MS; Lange T; Estrada JC; Pomicter AD; Eiring AM; Kraft IL; Anderson DJ; Gu Z; Alikian M; Reid AG; Foroni L; Marin D; Druker BJ; O'Hare T; Deininger MW
    Blood; 2013 Jan; 121(3):489-98. PubMed ID: 23223358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.
    Seman ZA; Ahid F; Kamaluddin NR; Sahid ENM; Esa E; Said SSM; Azman N; Mat WKDW; Abdullah J; Ali NA; Khalid MKNM; Yusoff YM
    BMC Res Notes; 2024 Apr; 17(1):111. PubMed ID: 38643202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
    Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
    BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a novel NGS based BCR::ABL1 kinase domain mutation detection assay in Indian cohort.
    Chaudhary P; Chaudhary S; Patel F; Patel S; Vaishnani T; Trivedi N; Patel D; Sonagara T; Hirapara A; Vyas K; Patel L; Kumar R; Chakraborty N; Sharma D; Suthar J; Kamdar P; Jajodia E; Ahmad F; Arora N
    Sci Rep; 2024 Jul; 14(1):15745. PubMed ID: 38977756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand.
    Limsuwanachot N; Kongruang A; Rerkamnuaychoke B; Singdong R; Niparuck P; Jootar S; Siriboonpiputtana T
    Asian Pac J Cancer Prev; 2020 Jul; 21(7):2003-2012. PubMed ID: 32711426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.